Market closed
Rallybio/$RLYB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Rallybio
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
Ticker
$RLYB
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
25
Website
Rallybio Metrics
BasicAdvanced
$11M
-
-$1.33
-1.45
-
Price and volume
Market cap
$11M
Beta
-1.45
52-week high
$2.01
52-week low
$0.22
Average daily volume
136K
Financial strength
Current ratio
10.868
Quick ratio
10.495
Total debt to equity
0.25
Management effectiveness
Return on assets (TTM)
-38.91%
Return on equity (TTM)
-68.85%
Valuation
Price to revenue (TTM)
18.501
Price to book
0.18
Price to tangible book (TTM)
0.18
Price to free cash flow (TTM)
-0.239
Growth
Earnings per share change (TTM)
-28.03%
3-year earnings per share growth (CAGR)
-10.36%
What the Analysts think about Rallybio
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Rallybio stock.
Rallybio Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Rallybio Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Rallybio News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Rallybio stock?
Rallybio (RLYB) has a market cap of $11M as of April 16, 2025.
What is the P/E ratio for Rallybio stock?
The price to earnings (P/E) ratio for Rallybio (RLYB) stock is 0 as of April 16, 2025.
Does Rallybio stock pay dividends?
No, Rallybio (RLYB) stock does not pay dividends to its shareholders as of April 16, 2025.
When is the next Rallybio dividend payment date?
Rallybio (RLYB) stock does not pay dividends to its shareholders.
What is the beta indicator for Rallybio?
Rallybio (RLYB) has a beta rating of -1.45. This means that it has an inverse relation to market volatility.